实验室和临床中的新兴生物标志物：一种诊断糖尿病心力衰竭的新方法。
Emerging Biomarkers in the Laboratory and in Practice: A Novel Approach to Diagnosing Heart Failure in Diabetes.
机构信息
Diabetes Technology Society, Burlingame, CA, USA.
Kinexum, Harpers Ferry, WV, USA.
出版信息
J Diabetes Sci Technol. 2024 May;18(3):733-740. doi: 10.1177/19322968241227898. Epub 2024 Jan 31.
Abstract
The Biomarkers for the Diagnosis of Heart Failure in Diabetes webinar was hosted by Diabetes Technology Society on September 20, 2023, with the objective to review current evidence and management practices of biomarker screening for heart failure in people with diabetes. The webinar discussed (1) the four stages of heart failure, (2) diabetes and heart failure, (3) natriuretic peptide and troponin for diagnosing heart failure in diabetes, (4) emerging composite and investigational biomarkers for diagnosing heart failure, and (5) prevention of heart failure progression. Experts in heart failure from the fields of clinical chemistry, cardiology, and diabetology presented data about the importance of screening for heart failure as an often-unnoticed complication of people with type 1 and type 2 diabetes.
摘要
《糖尿病患者心力衰竭诊断的生物标志物》网络研讨会由糖尿病技术学会于 2023 年 9 月 20 日主办，旨在回顾当前有关糖尿病患者心力衰竭生物标志物筛查的证据和管理实践。该网络研讨会讨论了（1）心力衰竭的四个阶段，（2）糖尿病与心力衰竭，（3）用于诊断糖尿病心力衰竭的利钠肽和肌钙蛋白，（4）用于诊断心力衰竭的新兴综合和研究性生物标志物，以及（5）心力衰竭进展的预防。来自临床化学、心脏病学和糖尿病学领域的心力衰竭专家介绍了筛查心力衰竭的重要性的数据，心力衰竭是 1 型和 2 型糖尿病患者常常被忽视的并发症。
相似文献
1
Emerging Biomarkers in the Laboratory and in Practice: A Novel Approach to Diagnosing Heart Failure in Diabetes.实验室和临床中的新兴生物标志物：一种诊断糖尿病心力衰竭的新方法。
J Diabetes Sci Technol. 2024 May;18(3):733-740. doi: 10.1177/19322968241227898. Epub 2024 Jan 31.
2
Recommendations for early identification of heart failure in patients with diabetes: Consensus statement of the Swiss Society of Endocrinology and Diabetology and the Heart Failure Working Group of the Swiss Society of Cardiology.瑞士内分泌学会和糖尿病学会以及瑞士心脏病学会心力衰竭工作组关于早期识别糖尿病患者心力衰竭的建议：共识声明。
Swiss Med Wkly. 2024 Oct 9;154:4000. doi: 10.57187/s.4000.
3
The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting.利钠肽在心力衰竭中的诊断准确性：急性护理环境中的系统评价和诊断性荟萃分析
BMJ. 2015 Mar 4;350:h910. doi: 10.1136/bmj.h910.
4
Guideline for the Use of Natriuretic Peptides in the Early Diagnosis and Management of Heart Failure in Primary Care .基层医疗中利钠肽在心力衰竭早期诊断与管理中的应用指南
Balkan Med J. 2025 Mar 3;42(2):94-107. doi: 10.4274/balkanmedj.galenos.2025.2024-12-110.
5
6
B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.慢性心力衰竭门诊患者中B型利钠肽引导治疗与症状引导治疗的系统评价及荟萃分析
J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):122-34. doi: 10.2459/JCM.0b013e328364bde1.
7
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.糖尿病性心肌病变的超声心动图表型：ARISE-HF试验中15个月随访期内的演变
Cardiovasc Diabetol. 2025 Jan 13;24(1):16. doi: 10.1186/s12933-024-02554-y.
8
Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis.利钠肽对胸腔积液患者心力衰竭的诊断准确性：一项系统评价和更新的荟萃分析
PLoS One. 2015 Aug 5;10(8):e0134376. doi: 10.1371/journal.pone.0134376. eCollection 2015.
9
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
10
Application of the American Heart Association/American College of Cardiology/Heart Failure Society of America Heart Failure Staging Guidelines in Adults With Chronic Kidney Disease.美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭分期指南在慢性肾脏病成人患者中的应用
J Am Heart Assoc. 2025 Jul 15;14(14):e039868. doi: 10.1161/JAHA.124.039868. Epub 2025 Jul 3.
本文引用的文献
1
Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society.糖尿病患者心力衰竭诊断的生物标志物：糖尿病技术协会共识报告
Prog Cardiovasc Dis. 2023 Jul-Aug;79:65-79. doi: 10.1016/j.pcad.2023.05.002. Epub 2023 May 11.
2
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.2023年美国心脏病学会射血分数保留的心力衰竭管理专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19.
3
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study.使用心脏生物标志物对心力衰竭前期阶段进行重新分类：ARIC 研究。
JACC Heart Fail. 2023 Apr;11(4):440-450. doi: 10.1016/j.jchf.2022.12.005. Epub 2023 Feb 1.
4
Real-World Evidence Supports Higher Prevalence of Heart Failure Among Persons With Type 1 and Type 2 Diabetes Compared With the General Population.真实世界证据表明，与普通人群相比，1型和2型糖尿病患者中心力衰竭的患病率更高。
J Diabetes Sci Technol. 2023 May;17(3):864-865. doi: 10.1177/19322968231155165. Epub 2023 Feb 23.
5
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.心力衰竭：糖尿病被低估的并发症。美国糖尿病协会共识报告。
Diabetes Care. 2022 Jul 7;45(7):1670-1690. doi: 10.2337/dci22-0014.
6
Validation of the WATCH-DM and TRS-HF Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis.验证 WATCH-DM 和 TRS-HF 评分在预测 2 型糖尿病成人心力衰竭住院风险中的作用：一项多队列分析。
J Am Heart Assoc. 2022 Jun 7;11(11):e024094. doi: 10.1161/JAHA.121.024094. Epub 2022 Jun 3.
7
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure.循环 sST2、hs-cTnT 和 NT-proBNP 水平及其对慢性心力衰竭女性和男性患者的预后价值。
ESC Heart Fail. 2022 Aug;9(4):2084-2095. doi: 10.1002/ehf2.13883. Epub 2022 May 5.
8
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
9
Biological variation, reference change values and index of individuality of GDF-15.生长分化因子-15的生物学变异、参考变化值及个体性指数
Clin Chem Lab Med. 2021 Oct 14;60(4):593-596. doi: 10.1515/cclm-2021-0769. Print 2022 Mar 28.
10
Biomarkers for the diagnosis and management of heart failure.心力衰竭的诊断和管理生物标志物。
Heart Fail Rev. 2022 Mar;27(2):625-643. doi: 10.1007/s10741-021-10105-w. Epub 2021 Apr 14.
Zotero 插件